Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

GBIO

Generation Bio Co

Feb 06 • 04:00PM ET

5.34

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM SGMO SRPT BLUE PSTX IOVA ADVM

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-9.35	Insider Own	37.13%	Shs Outstand	6.74M	Perf Week	-
Market Cap	35.99M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	0.00%	Shs Float	5.14M	Perf Month	-5.49%
Enterprise Value	-27.53M	PEG	-	EPS next Q	-6.85	Inst Own	41.09%	Short Float	0.15%	Perf Quarter	-3.61%
Income	-62.63M	P/S	2.36	EPS this Y	34.42%	Inst Trans	-6.13%	Short Ratio	0.09	Perf Half Y	-19.82%
Sales	15.27M	P/B	0.71	EPS next Y	84.17%	ROA	-33.79%	Short Interest	0.01M	Perf YTD	-5.99%
Book/sh	7.51	P/C	0.40	EPS next 5Y	53.82%	ROE	-80.81%	52W High	8.20 -34.88%	Perf Year	-33.72%
Cash/sh	13.30	P/FCF	-	EPS past 3/5Y	2.26% -8.29%	ROIC	-89.08%	52W Low	3.00 77.76%	Perf 3Y	-92.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	68.24%	Volatility	4.65% 2.78%	Perf 5Y	-98.38%
Dividend TTM	-	EV/Sales	-1.80	EPS Y/Y TTM	57.32%	Oper. Margin	-512.53%	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.44	Sales Y/Y TTM	-17.82%	Profit Margin	-410.13%	RSI (14)	39.71	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.44	EPS Q/Q	64.28%	SMA20	-4.85%	Beta	2.00	Target Price	5.00
Payout	-	Debt/Eq	0.52	Sales Q/Q	-78.90%	SMA50	-2.70%	Rel Volume	0.00	Prev Close	5.34
Employees	115	LT Debt/Eq	0.39	Earnings	Nov 05 AMC	SMA200	5.22%	Avg Volume	84.44K	Price	5.34
IPO	Jun 12, 2020	Option/Short	No / No	EPS/Sales Surpr.	73.97% 141.52%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Upgrade	Wedbush	Neutral → Outperform	$5.50
Dec-16-25	Downgrade	Jefferies	Buy → Hold	$5
Aug-13-25	Downgrade	Wedbush	Outperform → Neutral	$7
Oct-19-23	Downgrade	TD Cowen	Outperform → Market Perform
Nov-08-22	Initiated	Canaccord Genuity	Buy	$9
Dec-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
Feb-24-21	Initiated	William Blair	Outperform
Feb-18-21	Initiated	Needham	Buy	$50
Jul-07-20	Initiated	Wedbush	Outperform	$31
Jul-07-20	Initiated	JP Morgan	Overweight	$28
Jul-07-20	Initiated	Jefferies	Buy	$38
Jul-07-20	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-29-26 07:00AM	Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs (Business Wire)
Jan-23-26 11:01AM	Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-13-26 01:52AM	Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-16-25 11:21AM	Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
03:03AM	Zombie biotech buyer Xoma to acquire Generation Bio (BioPharma Dive)
05:00PM	Loading…
Dec-15-25 05:00PM	XOMA Royalty Enters into Agreement to Acquire Generation Bio (GlobeNewswire)
Nov-05-25 04:05PM	Generation Bio Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 06:30AM	Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors (Business Wire)
Oct-22-25 04:05PM	Generation Bio Announces CEO Transition (GlobeNewswire)
Aug-15-25 07:20AM	Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial (BioPharma Dive) -5.56%
Aug-12-25 05:30PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +63.21%
04:05PM	Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-18-25 08:35AM	Generation Bio Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -22.08%
Jul-07-25 04:05PM	Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.94%
06:59AM	Loading…
May-28-25 06:59AM	Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-07-25 05:35PM	Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.77%
04:05PM	Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results (GlobeNewswire)
Apr-02-25 06:59AM	Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference (GlobeNewswire)
Mar-13-25 05:15PM	Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.25%
04:05PM	Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 06:59AM	Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-06-25 04:30PM	Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases (GlobeNewswire) -8.77%
Nov-06-24 05:40PM	Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +9.59%
04:05PM	Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-22-24 06:59AM	Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress (GlobeNewswire)
Sep-12-24 04:05PM	Generation Bio to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-24 11:54PM	GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) -9.39% +8.11%
07:35PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Generation Bio Reports Second Quarter 2024 Financial Results (GlobeNewswire)
06:59AM	Loading…
Aug-06-24 06:59AM	Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) +7.46%
Jun-14-24 06:59AM	Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit (GlobeNewswire) -19.88%
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-13-24 09:54PM	GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) -5.02% +24.65%
05:15PM	Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 06:59AM	Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting (GlobeNewswire) +5.16%
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-22-24 05:31PM	Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (GlobeNewswire) +16.01%
Apr-02-24 06:59AM	Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-08-24 04:32AM	Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes (GuruFocus.com) +18.98%
Mar-06-24 10:52PM	GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +6.50%
05:40PM	Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 06:59AM	Generation Bio to Present at the 2024 TD Cowen Health Care Conference (GlobeNewswire) +6.79%
Jan-03-24 04:05PM	Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-23 03:05AM	Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO) (GuruFocus.com) +24.81%
Nov-29-23 08:41AM	Generation Bio eliminates 40% of staff, including 2 C-suite execs, in pivot to ex-liver targets (FierceBiotech.com)
06:59AM	Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms (GlobeNewswire)
Nov-09-23 04:15PM	Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire) -11.11% +10.58%
Oct-26-23 06:59AM	Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform (GlobeNewswire)
Oct-18-23 06:59AM	Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel Immune-Quiet DNA (GlobeNewswire) -22.51%
Sep-19-23 07:30AM	Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit (GlobeNewswire)
Aug-03-23 08:49AM	Insider Buyers Lose US$80k As Generation Bio Sheds US$37m (Simply Wall St.)
07:30AM	Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Aug-02-23 07:05PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.49%
04:15PM	Generation Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
May-31-23 07:30AM	Generation Bio to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -7.41%
May-10-23 06:05PM	Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.29%
04:15PM	Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 04:15PM	Generation Bio to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-11-23 07:30AM	Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.21%
Apr-10-23 09:40AM	Here's Why We're Not At All Concerned With Generation Bio's (NASDAQ:GBIO) Cash Burn Situation (Simply Wall St.)
Apr-05-23 07:30AM	Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer (GlobeNewswire)
Mar-24-23 03:02PM	Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio (Zacks)
Mar-23-23 10:43AM	Moderna, Generation Bio Collaborate To Develop Non-Viral Genetic Medicines (Benzinga) +28.87%
07:29AM	UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID (Reuters)
07:00AM	Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines (GlobeNewswire)
Mar-21-23 04:15PM	Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines (GlobeNewswire)
Feb-27-23 07:30AM	Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-24-23 07:18AM	Bullish insiders bet US$536k on Generation Bio Co. (NASDAQ:GBIO) (Simply Wall St.) -9.44%
Feb-23-23 04:28PM	Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-03-23 04:30PM	Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +26.68%
Dec-05-22 09:55AM	Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect? (Zacks) -12.85%
Nov-17-22 09:55AM	Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:15PM	Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire) +12.88%
Nov-01-22 08:07AM	We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely (Simply Wall St.) +9.57%
Sep-22-22 07:30AM	Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-20-22 07:30AM	Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer (GlobeNewswire)
Sep-17-22 08:12AM	A number of insiders bought Generation Bio Co. (NASDAQ:GBIO) stock last year, which is great news for shareholders (Simply Wall St.)
Aug-04-22 05:45PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.33%
04:15PM	Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire) +17.55%
Jul-18-22 07:30AM	Generation Bio Appoints Dannielle Appelhans to Its Board of Directors (GlobeNewswire) -5.99%
Jul-11-22 09:55AM	Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High? (Zacks) -8.54%
Jun-21-22 08:30AM	Generation Bio Announces Update to Its GMP Manufacturing Strategy (GlobeNewswire) +10.02%
Jun-02-22 07:30AM	Generation Bio to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-25-22 06:37AM	Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation (Simply Wall St.)
May-05-22 07:05PM	Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.17% -11.65%
04:15PM	Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-05-22 07:30AM	Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-22 12:00PM	Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why (Zacks)
10:00AM	How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505% (Zacks)
Mar-02-22 07:30AM	Generation Bio to Participate in 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-24-22 04:20PM	Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +9.09% +10.96%
Feb-10-22 07:30AM	Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer (GlobeNewswire) -11.51%
Jan-05-22 07:30AM	Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.52%
Dec-28-21 07:37PM	SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders (Business Wire) -8.40%

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Open in Screener

VKTX

Viking Therapeutics Inc

Feb 13 • 04:00PM ET

29.00

-1.49 -4.89 %

Healthcare • Biotechnology • USA • NASD

VKTX Viking Therapeutics Inc daily Stock Chart

Peers: MDGL AKRO GLMD AKBA ATON ARDX BOLD TVRD EYPT KYNB

| Held by: VTI VB XBI VBK VXF SCHA IWR VHT IWD IWS

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	2.95%	Shs Outstand	114.79M	Perf Week	1.97%
Market Cap	3.35B	Forward P/E	-	EPS next Y	-4.57	Insider Trans	-12.25%	Shs Float	112.14M	Perf Month	-15.55%
Enterprise Value	2.65B	PEG	-	EPS next Q	-1.00	Inst Own	61.83%	Short Float	23.24%	Perf Quarter	-28.89%
Income	-359.64M	P/S	-	EPS this Y	-32.23%	Inst Trans	-2.05%	Short Ratio	8.41	Perf Half Y	-27.93%
Sales	0.00M	P/B	5.21	EPS next Y	-8.41%	ROA	-44.29%	Short Interest	26.06M	Perf YTD	-17.57%
Book/sh	5.57	P/C	4.75	EPS next 5Y	-9.28%	ROE	-47.34%	52W High	43.15 -32.79%	Perf Year	-1.69%
Cash/sh	6.11	P/FCF	-	EPS past 3/5Y	-52.71% -42.46%	ROIC	-56.28%	52W Low	18.92 53.28%	Perf 3Y	172.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.73% 6.44%	Perf 5Y	245.65%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-215.49%	Oper. Margin	-	ATR (14)	2.16	Perf 10Y	1646.99%
Dividend Ex-Date	-	Quick Ratio	9.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.54	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	9.33	EPS Q/Q	-334.74%	SMA20	-4.87%	Beta	0.77	Target Price	92.94
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-12.78%	Rel Volume	0.95	Prev Close	30.49
Employees	53	LT Debt/Eq	0.00	Earnings	Feb 11 AMC	SMA200	-7.41%	Avg Volume	3.10M	Price	29.00
IPO	Apr 29, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-55.02% -	Trades		Volume	2,931,412	Change	-4.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Initiated	Canaccord Genuity	Buy	$106
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$104
Apr-08-25	Initiated	Goldman	Neutral	$30
Feb-13-25	Initiated	Scotiabank	Sector Outperform	$102
Feb-07-25	Initiated	Citigroup	Neutral	$38
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy	$109
Nov-04-24	Reiterated	H.C. Wainwright	Buy	$90 → $102
Sep-11-24	Initiated	JP Morgan	Overweight	$80
Jun-27-24	Initiated	Morgan Stanley	Overweight	$105
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$115 → $116
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14

Show Previous Ratings

Today 10:26AM	NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock? (Zacks)
09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-13-26 11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 11:31AM	Viking Therapeutics Stock Soars: What's Driving The Momentum? (Benzinga) +6.80%
10:07AM	Stocks Mixed on Strength in Chipmakers and Weakness in Cisco Systems (Barchart)
08:42AM	Loading…
08:42AM	How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report (Zacks)
08:30AM	Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
08:03AM	VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates (Zacks)
12:03AM	Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
Feb-11-26 06:02PM	Viking Therapeutics Q4 Earnings Call Highlights (MarketBeat)
05:13PM	Cisco Systems, Applovin, Viking: After-Hours Movers (Yahoo Finance Video)
04:33PM	Viking Therapeutics Stock Climbs After Q4 Report: Details (Benzinga)
04:16PM	Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
09:54AM	Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook? (Zacks)
Feb-10-26 10:49AM	Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 (Zacks)
11:30AM	Loading…
Feb-09-26 11:30AM	Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week (Benzinga)
10:12AM	Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why (Investor's Business Daily)
09:55AM	Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead? (Zacks)
Feb-07-26 05:22PM	Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown (Investor's Business Daily)
Feb-04-26 04:05PM	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 (PR Newswire) -11.06%
Feb-03-26 07:08PM	The Smartest Growth Stock to Buy With $30 Right Now (Motley Fool)
Feb-02-26 11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
Jan-30-26 05:45PM	Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market (Zacks)
10:06AM	Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? (Zacks)
08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
Jan-28-26 09:09AM	Roche Reports Upbeat Efficacy Data From Phase II Obesity Study (Zacks)
Jan-27-26 01:35PM	2 Biotech Stocks Set to Rebound in 2026 (Motley Fool)
09:41AM	Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet? (Zacks)
Jan-26-26 11:35AM	Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? (Motley Fool)
09:15AM	How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results? (Zacks)
03:14AM	Loading…
03:14AM	Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline (Insider Monkey)
Jan-24-26 08:35PM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
01:35PM	The Best Stocks to Invest $40 in to Start the New Year Off Right (Motley Fool)
Jan-23-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts (Zacks) -5.49%
05:30AM	Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 (Motley Fool)
Jan-22-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts (Zacks)
Jan-21-26 03:41PM	2 Bargain Stocks You Can Buy for Less Than $100 Right Now (Motley Fool)
10:50AM	1 Stock That Could Soar by 175%, According to Wall Street (Motley Fool)
Jan-20-26 03:25PM	What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? (Motley Fool)
08:28AM	3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 (MarketBeat)
Jan-19-26 03:23PM	Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (MarketBeat)
09:59AM	Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already? (Zacks)
Jan-16-26 10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks) +6.40%
Jan-15-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks) -7.16%
01:11PM	Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? (Benzinga)
10:17AM	How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results? (Zacks)
05:10AM	Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook (Insider Monkey)
Jan-14-26 01:25PM	Stocks Drop, Energy Sector Rises As Crude Eyes 6th Day Of Gains: What's Moving Markets Wednesday? (Benzinga) +11.89%
Jan-13-26 09:58AM	Novo Nordisk Soars 19% in a Month: How Should You Play the Stock? (Zacks)
09:06AM	Jim Cramer Says "I'm a Eli Lilly Guy" When Asked About Viking Therapeutics (Insider Monkey)
Jan-12-26 07:00AM	Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity (PR Newswire)
Jan-09-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know (Zacks)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
07:12AM	Viking Therapeutics completes enrollment in trial of VK2735 (TipRanks)
Jan-08-26 08:38PM	Lightning Round: QXO is a buy, says Jim Cramer (CNBC TV)
09:30AM	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
07:00AM	Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PR Newswire)
Jan-07-26 07:00AM	Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer (PR Newswire)
Jan-06-26 09:41AM	Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026? (Zacks)
Jan-05-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -9.26%
04:03PM	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks)
08:34AM	Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026? (Zacks)
Jan-02-26 09:01AM	Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III (Zacks)
Dec-31-25 09:15AM	2 Beaten-Down Stocks That Could Bounce Back in 2026 (Motley Fool)
08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-30-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Dec-29-25 02:34PM	This Small But Mighty Stock Could Surprise Investors in 2026 (Barchart)
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:01PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? (Zacks)
08:58AM	Premarket Movers: Albemarle Gaining Momentum on Lithium Boom (24/7 Wall St.)
Dec-22-25 06:46PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
06:50AM	Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) (Insider Monkey)
Dec-18-25 01:13PM	Viking Therapeutics, Inc. (VKTX): A Bull Case Theory (Insider Monkey)
12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
09:53AM	Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share? (Zacks)
Dec-16-25 01:35PM	1 Bold Prediction for Viking Therapeutics in 2026 (Motley Fool)
10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Dec-15-25 11:11PM	Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development (Insider Monkey)
05:45PM	Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-13-25 04:30AM	My Top 10 Stocks to Buy for 2026 (Motley Fool)
Dec-12-25 11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
07:44AM	This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street (Insider Monkey)
07:35AM	3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 (Motley Fool)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
07:10AM	Bullish Analysts Just Cant Quit Strategy Shares After 60% Rout (Bloomberg)
Dec-09-25 09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily) +8.92%
11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
Dec-03-25 09:26AM	Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? (Zacks)
Dec-02-25 12:28PM	LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website (Zacks)
Dec-01-25 09:26AM	VKTX Stock Rises 34% in Three Months: Here's What You Should Know (Zacks) -6.14%

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05 08:31 PM
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,405	409,190	Jan 05 08:31 PM
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05 08:28 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05 08:25 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05 08:25 PM
MARIANNA MANCINI	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,406		Jan 05 04:32 PM
GREG ZANTE	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,470		Jan 05 04:30 PM
BRIAN LIAN	Officer	Jan 05 '26	Proposed Sale	32.96	233,409	7,692,134		Jan 05 04:29 PM
MATTHEW W. FOEHR	Director	Jan 02 '26	Proposed Sale	35.11	16,000	561,694		Jan 02 04:46 PM
Mancini Marianna	Chief Operating Officer	Oct 28 '25	Sale	35.00	6,185	216,492	382,467	Oct 28 07:51 PM
Rowland Charles A Jr	Director	Oct 27 '25	Sale	35.57	60,000	2,134,278	30,000	Oct 28 07:49 PM
Lian Brian	President & CEO	Oct 28 '25	Sale	35.01	38,989	1,364,923	2,419,109	Oct 28 07:48 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '25	Sale	35.00	6,185	216,481	173,592	Oct 28 07:47 PM
GREG ZANTE	Officer	Oct 28 '25	Proposed Sale	35.01	6,185	216,531		Oct 28 04:34 PM
MARIANNA MANCINI	Officer	Oct 28 '25	Proposed Sale	35.00	6,185	216,492		Oct 28 04:32 PM
BRIAN LIAN	Officer	Oct 28 '25	Proposed Sale	35.01	38,989	1,364,923		Oct 28 04:27 PM
CHARLES A ROWLAND JR.	Director	Oct 27 '25	Proposed Sale	35.57	60,000	2,134,278		Oct 27 04:25 PM
Lian Brian	President & CEO	Jul 03 '25	Sale	27.80	26,889	747,633	2,388,014	Jul 03 03:31 PM
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03 03:31 PM
Mancini Marianna	Chief Operating Officer	Jul 03 '25	Sale	27.77	4,266	118,473	377,535	Jul 03 03:30 PM
GREG ZANTE	Officer	Jul 03 '25	Proposed Sale	27.76	4,266	118,428		Jul 03 01:07 PM
MARIANNA MANCINI	Officer	Jul 03 '25	Proposed Sale	27.77	4,266	118,473		Jul 03 01:05 PM
BRIAN LIAN	Officer	Jul 03 '25	Proposed Sale	27.80	26,889	747,633		Jul 03 01:01 PM
FOEHR MATTHEW W	Director	Apr 11 '25	Option Exercise	8.00	20,786	166,288	132,036	Apr 14 07:26 PM
Rouan Sarah Kathryn	Director	Mar 31 '25	Buy	24.15	1,240	29,943	1,240	Apr 02 06:29 PM

GBIO

Generation Bio Co

VKTX

Viking Therapeutics Inc

Upgrade your FINVIZ experience